Raymond Hohl
Overview
Explore the profile of Raymond Hohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khosla A, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, et al.
Blood Transfus
. 2024 Oct;
22(6):525-528.
PMID: 39447189
No abstract available.
2.
Zulch E, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, et al.
Leuk Res
. 2024 Jun;
143:107530.
PMID: 38852515
Primary graft failure (PGF) and multi-lineage cytopenia (MLC) increase the risk of nonrelapse mortality in allogeneic hematopoietic cell transplants (HCT). We evaluated the impact of post-transplant cyclophosphamide (PTCy) and splenomegaly...
3.
Guare E, Hale C, Sivik J, Lehman E, Inoue Y, Rakszawski K, et al.
Transpl Infect Dis
. 2024 Jan;
26(2):e14241.
PMID: 38269469
Background: Bacterial prophylaxis with a fluoroquinolone (FQ) during autologous stem cell transplant (ASCT) is common, although not standardized among transplant centers. The addition of doxycycline (doxy) to FQ prophylaxis was...
4.
Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, Wirk B, et al.
Ann Hematol
. 2022 Dec;
102(3):613-620.
PMID: 36527460
Full donor T-cell chimerism (FDTCC) after allogeneic stem cell transplant (allo-SCT) has been associated with improved outcomes in hematologic malignancy. We studied if donor human leukocyte antigen (HLA) mismatch improves...
5.
Shah N, Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, et al.
Leuk Res
. 2022 Oct;
123:106969.
PMID: 36306723
No abstract available.
6.
Wang M, Wasserman E, Geyer N, Carroll R, Zhao S, Zhang L, et al.
BMC Cancer
. 2020 May;
20(1):394.
PMID: 32375682
Background: Spatial heterogeneity of prostate cancer-specific mortality in Pennsylvania remains unclear. We utilized advanced geospatial survival regressions to examine spatial variation of prostate cancer-specific mortality in PA and evaluate potential...
7.
Allen B, Bodeker K, Smith M, Monga V, Sandhu S, Hohl R, et al.
Clin Cancer Res
. 2019 Aug;
25(22):6590-6597.
PMID: 31427282
Purpose: Standard treatment for glioblastoma (GBM) includes surgery, radiation therapy (RT), and temozolomide (TMZ), yielding a median overall survival (OS) of approximately 14 months. Preclinical models suggest that pharmacologic ascorbate...
8.
Osborn-Heaford H, Murthy S, Gu L, Larson-Casey J, Ryan A, Shi L, et al.
Free Radic Biol Med
. 2015 May;
86:47-56.
PMID: 25958207
Fibrotic remodeling in lung injury is a major cause of morbidity. The mechanism that mediates the ongoing fibrosis is unclear, and there is no available treatment to abate the aberrant...
9.
Malchenko S, Seftor E, Nikolsky Y, Hasegawa S, Kuo S, Stevens J, et al.
Sarcoma
. 2012 Mar;
2012:820254.
PMID: 22448124
Chondrosarcomas are among the most malignant skeletal tumors. Dedifferentiated chondrosarcoma is a highly aggressive subtype of chondrosarcoma, with lung metastases developing within a few months of diagnosis in 90% of...
10.
Messing E, Gee J, Saltzstein D, Kim K, diSantAgnese A, Kolesar J, et al.
Cancer Prev Res (Phila)
. 2012 Feb;
5(4):621-30.
PMID: 22293631
The soy compound genistein has been observed preclinically to inhibit bladder cancer growth with one potential mechanism being the inhibition of epidermal growth factor receptor phosphorylation (p-EGFR). A phase 2...